Background: Several studies have shown that the long noncoding RNA (lncRNA) CBR3-AS1 is overexpressed in various cancers and is playing an oncogene role. This meta-analysis aims to elucidate the relationship between lncRNA CBR3-AS1 expression and the prognosis and clinicopathological features of cancer patients.
Methods: A comprehensive and systematic search was conducted in PubMed, Web of Science, Cochrane Library, and EMBASE database. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were employed to evaluate the association between lncRNA CBR3-AS1 expression and clinical outcomes and clinicopathological features in cancer patients.
Results: This meta-analysis finally enrolled 9 studies comprising 800 cancer patients. The combined results indicated that lncRNA CBR3-AS1 overexpression was significantly associated with shorter overall survival (pooled hazard ratios = 1.69, 95% CI 1.28-2.21, P < .001). Furthermore, elevated lncRNA CBR3-AS1 expression was closely correlated with larger tumor size (large vs small OR = 2.17, 95% CI: 1.50-3.14, P < .0001), lymph node metastasis (yes vs no OR = 2.75, 95% CI: 1.67-4.51, P < .0001), distant metastasis (yes vs no OR = 3.08, 95% CI: 1.82-5.23, P < .0001), and advanced tumour, node, metastasis stage (III/IV vs I/II OR = 2.82, 95% CI: 1.68-4.75, P < .0001).
Conclusion: Upregulated expression of lncRNA CBR3-AS1 showed significant association with unfavorable survival and indicated worse clinicopathological outcomes in multiple kinds of human cancer, and therefore might serve as a promising prognosis biomarker and therapeutic target for cancers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576033 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000040361 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic value of lncRNA CBR3-AS1 for patients with cancer: A meta-analysis.
Medicine (Baltimore)
November 2024
Department of Spine Surgery, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, P.R. China.
Background: Several studies have shown that the long noncoding RNA (lncRNA) CBR3-AS1 is overexpressed in various cancers and is playing an oncogene role. This meta-analysis aims to elucidate the relationship between lncRNA CBR3-AS1 expression and the prognosis and clinicopathological features of cancer patients.
Methods: A comprehensive and systematic search was conducted in PubMed, Web of Science, Cochrane Library, and EMBASE database.
Trimetazidine Alleviates Bleomycin-Induced Pulmonary Fibrosis by Targeting the Long Noncoding RNA CBR3-AS1-Mediated miRNA-29 and Resistin-Like Molecule alpha 1: Deciphering a Novel Trifecta Role of LncRNA CBR3-AS1/miRNA-29/FIZZ1 Axis in Lung Fibrosis.
Drug Des Devel Ther
September 2024
Chemistry Department, Faculty of Science, Suez Canal University, Ismailia, Egypt.
Introduction: Pulmonary fibrosis (PF) and tissue remodeling can greatly impair pulmonary function and often lead to fatal outcomes.
Methodology: In the present study, we explored a novel molecular interplay of long noncoding (Lnc) RNA CBR3-AS1/ miRNA-29/ FIZZ1 axis in moderating the inflammatory processes, immunological responses, and oxidative stress pathways in bleomycin (BLM)-induced lung fibrosis. Furthermore, we investigated the pharmacological potential of Trimetazidine (TMZ) in ameliorating lung fibrosis.
LncRNA is associated with the BCR::ABL1 kinase independent mechanism of tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia patients.
Transl Cancer Res
July 2024
Department of Hematology, the First Hospital of Putian City, Putian, China.
Article Synopsis
- The study focuses on chronic myeloid leukemia (CML) patients who experience drug resistance that is not dependent on the BCR::ABL1 mutation, aiming to uncover the underlying mechanisms of this resistance to improve treatment strategies.
- Researchers conducted RNA sequencing to compare long non-coding RNA (lncRNA) and messenger RNA (mRNA) expression between patients who achieve deep molecular response (DMR) after treatment and those who do not (non-DMR).
- The analysis revealed distinct lncRNA profiles linked to drug resistance, indicating that overexpression of certain lncRNAs could play a role in TKI resistance among CML patients, leading to further investigation into potential therapeutic targets.
Allicin affects immunoreactivity of osteosarcoma cells through lncRNA CBR3-AS1.
Heliyon
June 2024
Department of Orthopedics, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250014, China.
Objective: To analyze the effect of allicin on the immunoreactivity of osteosarcoma (OS) cells and further explore whether its mechanism is related to the long non-coding Ribonucleic Acid (lncRNA) CBR3-AS1/miR-145-5p/GRP78 axis, so as to provide clinical evidence.
Methods: The human OS cell line Saos-2 was treated with allicin at 25, 50, and 100 μmol/L, respectively, to observe changes in cell biological behaviors. Subsequently, CBR3-AS1 abnormal expression vectors were constructed and transfected into Saos-2 to discuss their influence on OS.
Purpose: To investigate whether long noncoding RNAs (lncRNAs) are involved in the development or malignant behavior of ovarian high-grade serous carcinoma (HGSC), we attempted to identify lncRNAs specific to HGSC.
Methods: Total RNAs were isolated from HGSC, normal ovarian, and fallopian tube tissue samples and were subjected to a PCR array that can analyze 84 cancer-associated lncRNAs. The lncRNAs that were upregulated and downregulated in HGSC in comparison to multiple samples of normal ovary and fallopian tube were validated by real-time RT-PCR.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!